Dexamethasone Sodium Phosphate for Injection

Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is as follows: 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestation of inflammation. It can inhibit the accumulation of inflammatory cells, including macrophages and leukocytes at the site of inflammation, and inhibit phagocytosis, the release of lysosomal enzymes, and the synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effect: including preventing or inhibiting cell-mediated immune responses, delayed allergic reactions, reducing the number of T lymphocytes, monocytes, and eosinophils, reducing the ability of immunoglobulins to bind to cell surface receptors, and inhibiting the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and reducing the expansion of primary immune responses. This product also reduces the passage of immune complexes through the basement membrane and can reduce the concentration of complement components and immunoglobulins.

The main ingredients of this product and its chemical name: The main ingredient of this product is dexamethasone sodium phosphate. Its chemical name is: 16alpha;-methyl-11beta;,17alpha;,21-trihydroxy-9alpha;-fluoropregnane-1,4-diene-3,20-dione-21-phosphate disodium salt. Its molecular formula: C22H28FNa2O8P, molecular weight: 516.41.

It is mainly used for allergic and autoimmune inflammatory diseases. It is mostly used for connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, acute leukemia, etc. It is also used for the comprehensive treatment of certain severe infections and poisonings, and malignant lymphomas.

The general dose is 2-20 mg per intravenous injection; when intravenously dripping, it should be diluted with 5% glucose injection, and the drug can be repeated every 2-6 hours until the condition stabilizes, but large-dose continuous administration generally does not exceed 72 hours. It can also be used to relieve cerebral edema caused by malignant tumors. The first dose is 10 mg intravenously, followed by 4 mg intramuscularly every 6 hours. Generally, the patient can improve in 12-24 hours, and the dose is gradually reduced after 2-4 days, and the drug is stopped after 5-7 days. For brain tumors that are not suitable for surgery, the first dose can be 50 mg intravenously, and then 8 mg is repeated every 2 hours. After a few days, it is reduced to 2 mg per day, and it is given intravenously in 2-3 times. For intrathecal injection, 5 mg is injected each time, and the injection is injected once every 1-3 weeks; intra-articular injection is generally 0.8-4 mg each time, depending on the size of the joint cavity.

There are no obvious adverse reactions when glucocorticoids are used for replacement therapy with physiological doses. Adverse reactions mostly occur when pharmacological doses are used, and are closely related to the course of treatment, dose, type of medication, usage and route of administration. Common adverse reactions are as follows: 1. Long-term use may cause the following side effects: iatrogenic Cushing's syndrome face and body shape, weight gain, lower limb edema, purple lines, bleeding tendency, poor wound healing, acne, menstrual disorders, avascular necrosis of the humeral or femoral head, osteoporosis and fractures (including vertebral compression fractures, pathological fractures of long bones), muscle weakness, muscle atrophy, hypokalemia syndrome, gastrointestinal irritation (nausea, vomiting), pancreatitis, peptic ulcer or perforation, growth inhibition in children, glaucoma, cataracts, benign intracranial hypertension syndrome, impaired glucose tolerance and aggravation of diabetes. 2. Patients may experience mental symptoms: euphoria, agitation, delirium, restlessness, disorientation, and may also manifest as inhibition. Mental symptoms are prone to occur in people with chronic wasting diseases and those who have had mental disorders in the past. 3. Concurrent infection is the main adverse reaction of adrenocortical hormones. Fungi, tuberculosis, Staphylococcus, Proteus, Pseudomonas aeruginosa and various herpes viruses are the main ones. 4. Glucocorticoid withdrawal syndrome. Sometimes patients experience dizziness, fainting tendency, abdominal pain or back pain, low fever, loss of appetite, nausea, vomiting, muscle or joint pain, headache, fatigue, and weakness after stopping the drug. If careful examination can rule out adrenocortical insufficiency and recurrence of the original disease, it can be considered as a glucocorticoid dependence syndrome.

Patients with a history of allergy to this product and adrenal cortical hormones are contraindicated to use this product. It should be used in special circumstances after weighing the pros and cons and paying attention to the possibility of worsening of the condition: patients with hypertension, thrombosis, gastric and duodenal ulcers, mental illness, abnormal electrolyte metabolism, myocardial infarction, visceral surgery, glaucoma, etc. are generally not suitable for use.

1. When taken with barbiturates, phenytoin, and rifampicin, the metabolic promoting effect of this product is weakened. 2. When taken with salicylic acid drugs, their toxicity is increased. 3. It can weaken the effects of anticoagulants and oral hypoglycemic drugs, and the dosage should be adjusted.

Keep away from light and store in a sealed container.

1mg (as dexamethasone sodium phosphate)

Chongqing Lummy Pharmaceutical Co., Ltd.

• Founded in:

  1999-09-06

• Address:

  No. 99, Yuma Road, Nan'an District, Chongqing

• Tax NO.:

  915000006219193432

• Registered Funds:

  1,055,911,205 yuan

• Website:

  Log in to view

• Email:

  Log in to view